Human RPE65 Gene Therapy for Leber Congenital Amaurosis: Persistence of Early Visual Improvements and Safety at 1 Year

Human gene therapy with rAAV2-vector was performed for the RPE65 form of childhood blindness called Leber congenital amaurosis. In three contemporaneous studies by independent groups, the procedure was deemed safe and there was evidence of visual gain in the short term. At 12 months after treatment,...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Cideciyan, Artur V., Hauswirth, William W., Aleman, Tomas S., Kaushal, Shalesh, Schwartz, Sharon B., Boye, Sanford L., Windsor, Elizabeth A.M., Conlon, Thomas J., Sumaroka, Alexander, Pang, Ji-jing, Roman, Alejandro J., Byrne, Barry J., Jacobson, Samuel G.
Formato: Artigo
Lenguaje:Inglês
Publicado: Mary Ann Liebert, Inc. 2009
Materias:
Brief Reports
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC2829287/
https://ncbi.nlm.nih.gov/pubmed/19583479
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1089/hum.2009.086
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares